Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With OUD
NCT05817825
Recruiting
This study aims to test a remotely delivered IOP program ("SmartIOP") for OUD patients who are hospitalized for serious injection-related infections. This will be a pilot trial to assess the feasibility of the IOP program and examine OUD-related outcomes following discharge from the hospital.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Opioid Use Disorder, Serious Bacterial Infections
Register for Updates
Apple Women's Health Study
NCT04196595
Recruiting
This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Harvard T.H. Chan School of Public Health, Boston, Massachusetts
Conditions: Menstrual Cycle, Ovulation, Menstruation, Polycystic Ovary Syndrome, Infertility, Menopause, Reproduction, Reproductive Health
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Beverly Hospital, Beverly, Massachusetts
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT05701488
Recruiting
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Register for Updates
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
NCT05661084
Recruiting
This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/26/2024
Locations: Hinda and Arthur Marcus Institute for Aging Research, Boston, Massachusetts
Conditions: Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Register for Updates
Computational Neuroscience of Language Processing in the Human Brain
NCT05222594
Recruiting
Language is a signature human cognitive skill, but the precise computations that support language understanding remain unknown. This study aims to combine high-quality human neural data obtained through intracranial recordings with advances in computational modeling of human cognition to shed light on the construction and understanding of speech.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/26/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Language, Epilepsy
Register for Updates
Cortical-Basal Ganglia Speech Networks
NCT04286308
Recruiting
In this research study the researchers want to learn more about brain activity related to speech perception and production.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/26/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Parkinson Disease, Essential Tremor, Dystonia
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
NCT05795595
Recruiting
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Research Site 6, Boston, Massachusetts
Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Register for Updates
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
NCT05028829
Recruiting
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Liver Fibroses, Cirrhosis
Register for Updates
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
NCT03741777
Recruiting
According to the American Society of Anesthesiologists (ASA) fasting guideline for patients undergoing elective surgery, the 2-hour fasting period is suggested for clear oral fluid (including water, pulp-free juice and tea or coffee without milk). This guideline does not give any suggestions for proper volume of clear oral fluid intake. This study is a prospective randomized control trials in children aged 13 through 17 years who are scheduled for an elective upper GI endoscopy procedure in the... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
06/24/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Fasting, Gastric Emptying
Register for Updates
Permissive Hypotension After Cardiac Surgery
NCT06476613
Recruiting
The objective of this pilot randomized controlled trial is to demonstrate the feasibility of implementing a pragmatic clinical trial randomizing patients to permissive hypotension versus usual care and to determine the impact of permissive hypotension on vasopressor exposure, ICU length of stay, markers of end organ perfusion, and clinically relevant patient outcomes. The data collected from this pilot study will be used as preliminary data for study design and grant applications for a larger mu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Surgery
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Cholangiocarcinoma
Register for Updates